MorphoSys AG (MOR):製薬・医療:M&Aディール及び事業提携情報

◆英語タイトル:MorphoSys AG (MOR) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C5166
◆発行会社(調査会社):GlobalData
◆発行日:2018年9月
◆ページ数:67
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:ドイツ
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
MorphoSys AG (Morphosys) is a developer of monoclonal antibodies for therapeutic, diagnostic and research applications. The company’s pipeline product includes MOR208, MOR202, MOR103, MOR106, and MOR107. It drugs are used for the treatment of various types of cancers, psoriasis, rheumatoid arthritis, chronic obstructive pulmonary disease, asthma, solid tumors, eye disease, and other inflammatory diseases. Morphosys offers human combinatorial antibody library (HuCAL), a recombinant antibody technology which allows generation of therapeutic and diagnostic antibodies. The company provides clinical trials for cancer and inflammatory disorders. It also conducts research and development activities with pharmaceutical and biotechnology companies. The company owns a regional licensing agreement to develop and commercialize products in China, Taiwan, Hong Kong, and Macao. Morphosys is headquartered in Munich, Germany.

MorphoSys AG (MOR) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
MorphoSys AG, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
MorphoSys AG, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
MorphoSys AG, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
MorphoSys AG, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
MorphoSys AG, Medical Devices Deals, 2012 to YTD 2018 10
MorphoSys AG, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11
MorphoSys AG, Pharmaceuticals & Healthcare, Deal Details 13
Venture Financing 13
Lanthio Pharma Raises US$6 Million In Series A Financing 13
Partnerships 14
MorphoSys Enters into Agreement with LEO Pharma 14
MorphoSys Partners with University of Texas MD Anderson Cancer Center 15
MorphoSys Enters into Agreement with Immatics Biotech 16
MorphoSys Enters into Co-Development Agreement with G7 Therapeutics 17
MorphoSys And Temple University Enter Into Agreement To Discover Therapeutic Antibody 18
MorphoSys And Heptares Enter Into Agreement To Develop Antibody Therapeutics Targeting GPCRs 19
MorphoSys Enters Into Co-Development Agreement With Lanthio Pharma 20
Licensing Agreements 21
Novartis Pharma to Enter into Licensing Agreement with Galapagos and MorphoSys 21
I-Mab Biopharma Enters into Licensing Agreement with MorphoSys 23
MorphoSys Exercises Option to License Lanthipeptide Technology from Lanthio Pharma 24
Emergent BioSolutions Amends Licensing Agreement with MorphoSys for ES-414 25
MorphoSys Enters into Licensing Agreement with Merck Serono 27
MorphoSys Enters Into Licensing Agreement With GlaxoSmithKline (GSK) For MOR103 28
MorphoSys Enters Into Licensing Agreement With BioPharma Company For Slonomics Technology 30
Lanthio Pharma Enters Into Licensing Agreement With Tarix Pharma For Lanthionine Angiotensin-(1-7) Agonistic Peptide 31
Equity Offering 32
MorphoSys Raises USD239 Million in Public Offering of Shares 32
MorphoSys Raises USD124.3 Million in Private Placement of Shares 34
MorphoSys Completes Private Placement Of Shares For US$112.7 Million 35
Acquisition 37
MorphoSys Acquires Lanthio Pharma for USD22.5 Million 37
Bio-Rad Labs Completes Acquisition Of AbD Serotec From MorphoSys 38
MorphoSys AG – Key Competitors 39
MorphoSys AG – Key Employees 40
MorphoSys AG – Locations And Subsidiaries 41
Head Office 41
Other Locations & Subsidiaries 41
Recent Developments 42
Financial Announcements 42
Aug 02, 2018: MorphoSys re­ports se­cond quarter 2018 fin­an­cial res­ults 42
May 02, 2018: MorphoSy Reports First Quarter 2018 Results 44
Mar 13, 2018: MorphoSys Presents Results for Fiscal Year 2017 46
Nov 07, 2017: MorphoSys Announces Third Quarter 2017 Results 49
Aug 03, 2017: MorphoSys Reports Significant Progress in its Therapeutic Programs in Second Quarter of 2017 51
May 03, 2017: MorphoSys Reports Solid First Quarter 2017 53
Corporate Communications 55
Jul 24, 2018: MorphoSys Appoints Jennifer Herron as President of MorphoSys US and Executive Vice President, Global Commercial 55
May 17, 2018: Annual General Meeting of MorphoSys Elects New Supervisory Board Members 56
Apr 10, 2018: MorphoSys Nominates New Candidates for Supervisory Board 57
Oct 30, 2017: Dr. Markus Enzelberger Appointed MorphoSys’s Chief Scientific Officer 58
Product News 59
06/15/2018: MorphoSys Presents Updated Clinical Data for Anti-CD38 Antibody MOR202 in Multiple Myeloma at EHA 2018 59
05/18/2017: MorphoSys to Present Clinical Data on MOR-202 at Upcoming ASCO Annual Meeting 2017 60
05/17/2018: MorphoSys Announces Presentation of Clinical Data on CD38 antibody MOR202 at Upcoming EHA 2018 Conference 61
Product Approvals 62
Aug 08, 2018: MorphoSys and I-Mab Biopharma announce China IND submission of TJ202/MOR202 62
Clinical Trials 63
May 19, 2017: MorphoSys Announces First Results from Phase 1 Study with Lanthipeptide MOR107 in Healthy Volunteers 63
Feb 21, 2017: MorphoSys’s Subsidiary Lanthio Pharma Initiates First-in-Human Clinical Study with Lanthipeptide MOR107 64
Other Significant Developments 65
Sep 05, 2017: MorphoSys Presents Vision for Growth at its Capital Markets Day 65
Appendix 67
Methodology 67
About GlobalData 67
Contact Us 67
Disclaimer 67

List of Tables
MorphoSys AG, Pharmaceuticals & Healthcare, Key Facts, 2017 2
MorphoSys AG, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
MorphoSys AG, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
MorphoSys AG, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
MorphoSys AG, Deals By Therapy Area, 2012 to YTD 2018 9
MorphoSys AG, Medical Devices Deals, 2012 to YTD 2018 10
MorphoSys AG, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11
Lanthio Pharma Raises US$6 Million In Series A Financing 13
MorphoSys Enters into Agreement with LEO Pharma 14
MorphoSys Partners with University of Texas MD Anderson Cancer Center 15
MorphoSys Enters into Agreement with Immatics Biotech 16
MorphoSys Enters into Co-Development Agreement with G7 Therapeutics 17
MorphoSys And Temple University Enter Into Agreement To Discover Therapeutic Antibody 18
MorphoSys And Heptares Enter Into Agreement To Develop Antibody Therapeutics Targeting GPCRs 19
MorphoSys Enters Into Co-Development Agreement With Lanthio Pharma 20
Novartis Pharma to Enter into Licensing Agreement with Galapagos and MorphoSys 21
I-Mab Biopharma Enters into Licensing Agreement with MorphoSys 23
MorphoSys Exercises Option to License Lanthipeptide Technology from Lanthio Pharma 24
Emergent BioSolutions Amends Licensing Agreement with MorphoSys for ES-414 25
MorphoSys Enters into Licensing Agreement with Merck Serono 27
MorphoSys Enters Into Licensing Agreement With GlaxoSmithKline (GSK) For MOR103 28
MorphoSys Enters Into Licensing Agreement With BioPharma Company For Slonomics Technology 30
Lanthio Pharma Enters Into Licensing Agreement With Tarix Pharma For Lanthionine Angiotensin-(1-7) Agonistic Peptide 31
MorphoSys Raises USD239 Million in Public Offering of Shares 32
MorphoSys Raises USD124.3 Million in Private Placement of Shares 34
MorphoSys Completes Private Placement Of Shares For US$112.7 Million 35
MorphoSys Acquires Lanthio Pharma for USD22.5 Million 37
Bio-Rad Labs Completes Acquisition Of AbD Serotec From MorphoSys 38
MorphoSys AG, Key Competitors 39
MorphoSys AG, Key Employees 40
MorphoSys AG, Subsidiaries 41

List of Figures
MorphoSys AG, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
MorphoSys AG, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
MorphoSys AG, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
MorphoSys AG, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
MorphoSys AG, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
MorphoSys AG, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7
MorphoSys AG, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
MorphoSys AG, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
MorphoSys AG, Medical Devices Deals, 2012 to YTD 2018 10

★海外企業調査レポート[MorphoSys AG (MOR):製薬・医療:M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Cermaq Group AS:企業の戦略的SWOT分析
    Cermaq Group AS - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and servic …
  • OPKO Health Inc (OPK):医療機器:M&Aディール及び事業提携情報
    Summary OPKO Health Inc (OPKO) discovers, develops, manufactures and commercializes novel diagnostic technologies and pharmaceuticals. The company’s product portfolio includes point-of-care tests, laboratory developed tests (LDTs), molecular diagnostics tests, and proprietary pharmaceuticals and vac …
  • Herman Miller Inc (MLHR):企業の財務・戦略的SWOT分析
    Herman Miller Inc (MLHR) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses …
  • Keyence Corporation:企業の戦略・SWOT・財務情報
    Keyence Corporation - Strategy, SWOT and Corporate Finance Report Summary Keyence Corporation - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings a …
  • IHI Corporation:企業のM&A・事業提携・投資動向
    IHI Corporation - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's IHI Corporation Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A), divestm …
  • Airgas, Inc.:戦略・SWOT・企業財務分析
    Airgas, Inc. - Strategy, SWOT and Corporate Finance Report Summary Airgas, Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate a …
  • Guangdong Biolight Meditech Co Ltd (300246):医療機器:M&Aディール及び事業提携情報
    Summary Guangdong Biolight Meditech Co Ltd (Biolight) is a medical device company. The company operates in the business of research, development, production and sale of medical treatment monitors, medical consumables and healthcare solutions. It offers patient monitors, hemodialysis products and hom …
  • Aeris Resources Limited:企業の戦略・SWOT・財務分析
    Aeris Resources Limited - Strategy, SWOT and Corporate Finance Report Summary Aeris Resources Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service off …
  • Wolong Electric Group Co Ltd (600580):電力:M&Aディール及び事業提携情報
    Summary Wolong Electric Group Co Ltd (Wolong) is a motor manufacturing company that manufactures and sells motor products and home appliances. The company’s products include motors and electronic-controlled devices, traction transformers, traction rectifier unit of UMT, UHV power transformers, elect …
  • The Shipping Corporation of India Ltd (SCI):企業の財務・戦略的SWOT分析
    The Shipping Corporation of India Ltd (SCI) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key streng …
  • SoftBank Group Corp:企業の戦略・SWOT・財務情報
    SoftBank Group Corp - Strategy, SWOT and Corporate Finance Report Summary SoftBank Group Corp - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings a …
  • Whiting Petroleum Corp (WLL):企業の財務・戦略的SWOT分析
    Whiting Petroleum Corp (WLL) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknes …
  • AiCuris GmbH & Co KG:製薬・医療:M&Aディール及び事業提携情報
    Summary AiCuris GmbH & Co KG (AiCuris) a subsidiary of Santo Holding AG is a drug development company that discovers and develops antibacterial and antiviral agents for the treatment of life-threatening infectious diseases. The company’s pipeline products include antiviral and antibacterial agents f …
  • China Construction Bank Corp:企業の戦略・SWOT・財務情報
    China Construction Bank Corp - Strategy, SWOT and Corporate Finance Report Summary China Construction Bank Corp - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and s …
  • Schiller AG:企業の戦略的SWOT分析
    Schiller AG - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and services. …
  • ProSiebenSat.1 Media AG (PSM):企業の財務・戦略的SWOT分析
    ProSiebenSat.1 Media AG (PSM) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weakne …
  • Takara Bio Inc (4974):製薬・医療:M&Aディール及び事業提携情報
    Summary Takara Bio Inc (Takara), a subsidiary of Takara Holdings Inc, is a biotechnology company that develops, manufactures and distributes biotechnology research reagents and equipments for life sciences research. The company sells gene amplification system and offers scientific instruments. It of …
  • Regal Petroleum Plc (RPT):石油・ガス:M&Aディール及び事業提携情報
    Summary Regal Petroleum Plc (Regal), a subsidiary of Energees Investments Ltd, is an oil and gas company that conducts reviews on oil and gas projects. The company operates two gas and condensate fields such as Mekhediviska - Golotovschinska and Svyrydivske located in Dneipner-Donets basin in the no …
  • Damen Shipyards Group:企業の戦略・SWOT・財務情報
    Damen Shipyards Group - Strategy, SWOT and Corporate Finance Report Summary Damen Shipyards Group - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerin …
  • Horizon Discovery Group Plc (HZD):企業の財務・戦略的SWOT分析
    Summary Horizon Discovery Group Plc (Horizon Discovery) is a life science company that discovers and develops genetically-modified cell lines using a proprietary translational genomics platform. The company offers products such as cell lines, reference standards and in vivo models. It also offers se …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆